优化脑脊液生物学检查用于中枢神经系统淋巴瘤诊断
该研究基于371例训练队列和197例验证队列的脑脊液样本,评估常规细胞学、流式细胞术、PCR克隆性分析和细胞因子定量四种方法。研究提出两步法生物学算法:第一步常规细胞学联合流式细胞术,第二步根据结果和临床背景决定PCR和细胞因子定量。该算法未漏诊验证队列中任何中枢神经系统淋巴瘤样本,一年内可节省30%的PCR检测和20%的细胞因子定量检测。
要点
- 四种技术联合用于排除中枢神经系统淋巴瘤无额外价值,但在疑似病例中互补。
- 细胞因子定量在原发性中枢神经系统淋巴瘤中互补价值尤为突出。
- 两步法算法未漏诊验证队列中任何中枢神经系统淋巴瘤样本。
核心结论
- 四种技术联合对排除中枢神经系统淋巴瘤无益,但对疑似病例互补。
- 两步法算法未漏诊验证队列中任何中枢神经系统淋巴瘤样本。
- 应用该算法可节省30%的PCR检测和20%的细胞因子定量检测而不影响临床管理。
研究设计与样本
- 训练队列371例脑脊液样本,验证队列197例样本。
- 评估常规细胞学、流式细胞术、PCR克隆性分析和细胞因子定量四种方法。
- 样本按临床背景分类并比较各技术结果。
主要发现
- 四种技术联合用于排除中枢神经系统淋巴瘤无益。
- 四种技术在疑似中枢神经系统淋巴瘤病例中互补。
- 细胞因子定量在原发性中枢神经系统淋巴瘤中互补价值尤为突出。
关键数值与推荐
- 第一步:常规细胞学联合流式细胞术,结果快速且流式细胞术敏感。
- 第二步:根据第一步结果和临床背景决定是否行PCR和细胞因子定量。
临床怎么用
- 采用两步法:先做常规细胞学和流式细胞术,再根据结果和临床背景决定PCR和细胞因子定量。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosis of lymphoma leptomeningeal dissemination is challenging and relies on a wide array of methods. So far, no consensus biological guidelines are available. This increases the chance of intra- and interpractice variations, despite the shared concern to perform the minimum amount of tests while preserving clinically relevant results.We evaluated a training cohort of 371 cerebrospinal fluid (CSF) samples from patients with putative lymphomatous central nervous system (CNS) localization using conventional cytology (CC), flow cytometry (FCM), molecular clonality assesment by PCR and cytokine quantification (CQ). This led us to propose a biological algorithm, which was then verified on a validation cohort of 197 samples. The samples were classified according to the clinical context and the results of each technique were compared. Using all four techniques was not useful for exclusion diagnosis of CNS lymphoma (CNSL), but they proved complementary for cases with suspected CNSL. This was particularly true for CQ in primary CNSL. Overall, diagnosis can be obtained with a two-step approach. The first step comprises CC and FCM, as results are available quickly and FCM is a sensitive method. Both PCR and CQ can be postponed and performed in a second step, depending on the results from the first step and the clinical context.The proposed algorithm missed none of the CNSL samples of the validation cohort. Moreover, applying this algorithm would have spared 30% of PCR tests and 20% of CQ over a one-year period, without compromising clinical management.
引用
- Armand M, Costopoulos M, Osman J, et al. Optimization of CSF biological investigations for CNS lymphoma diagnosis. Am J Hematol. 2019. PMID: 31328307. doi:10.1002/ajh.25578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。